CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor.
R. Kumar, J. Mendonca, A. Shetty, Y. Yang, O. Owoyemi, L. C. Wilson, K. Boyapati, D. Topiwala, N. Thomas, H. Nguyen, J. Luo, C. J. Paller, S. R. Denmeade, M. A. Carducci, S. K. Kachhap
This study shows CRM1 regulates androgen receptor stability and DNA repair in prostate cancer, suggesting combination therapy with CRM1 and DNA repair inhibitors could be effective.
bioRxiv · Feb 13, 2024Cancer Biology